Most Read Articles
Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).

Normal alanine aminotransferase protects against hepatic events in CHB patients

24 Sep 2018

In patients with chronic hepatitis B (CHB) infections on nucleos(t)ide analogue (NA) treatment, normal on-treatment alanine aminotransferase (ALT) levels are associated with lower risks of hepatic events, a recent study has shown.

Using data from the Clinical Data Analysis and Reporting System of Hong Kong, researchers evaluated serial on-treatment ALT levels of 21,182 CHB patients (mean age 51±13 years). ALT <30 and <19 U/L in males and females, respectively, were considered as normal. Composite hepatic events, including hepatocellular carcinoma, were the study outcomes.

Of the participants, 10,438 achieved normal on-treatment ALT levels within 12 months of NA treatment, while 10,745 did not. Only a minority (3.0 percent; n=627) of the patients developed the primary study outcome of composite hepatic events over a mean follow-up period of 4.0±1.7 years. Most of these were hepatocellular carcinoma (2.4 percent; n=509).

The cumulative hepatic event rates were lower in those with normal vs elevated on-treatment ALT at different time points: 3 months (4.27 percent vs 4.76 percent; p=0.083), 6 months (3.60 percent vs 5.24 percent; p<0.001), 9 months (3.44 percent vs 5.57 percent; p<0.001) and 12 months (3.51 percent vs 5.70 percent; p<0.001).

These were confirmed in fully adjusted Cox regression analyses, which showed that the risk of composite hepatic events were significantly lower in those with normal vs elevated ALT at 3 months (adjusted hazard ratio [HR], 0.61; 95 percent CI, 0.49–0.77; p<0.001), 6 months (adjusted HR, 0.55; 0.45–0.67; p<0.001), 9 months (adjusted HR, 0.54; 0.44–0.65; p<0.001) and 12 months (adjusted HR, 0.51; 0.42–0.61; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).